Veterinary Dermatology Drugs Market Size, Share, and Trends 2024 to 2034

The global veterinary dermatology drugs market size is estimated at USD 8.20 billion in 2024 and is expected to reach around USD 19.28 billion by 2034, growing at a CAGR of 8.93% from 2024 to 2034. Drugs for veterinary dermatology are used to treat skin conditions or infections in animals, primarily pets and cattle.

Veterinary Dermatology Drugs Market Key Takeaways

• The North America region contributed 31% of the revenue share in 2023.
• By animal type, the companion animal market segment led and accounted for around 71% of total revenue, In 2023.
• By animal type, the livestock animal segment's revenue share recorded was the second-largest, In 2023.
• By route of administration, the oral segment led and contributed around 38% of total revenue, In 2023.
• By route of administration, the injectable category is anticipated to experience the fastest CAGR of around 10.70% throughout the projected period
• By indication, the parasitic infections segment has accounted market share of over 45.31% in 2023 and is anticipated to experience the fastest CAGR of around 10.5% from 2024 to 2034.
• By distribution channel, the hospital pharmacy led the industry and captured 45.50% of all sales in 2023. 
• By distribution channel, the e-commerce segment is predicted to experience the fastest CAGR of about 10.5% from 2024 to 2034.

U.S. Veterinary Dermatology Drugs Market Size and Growth 2024 to 2034

The U.S. verinary dermatology drugs market size was valued at USD 1.63 billion in 2023 and is expected to reach around USD 4.22 billion by 2034, expanding at a CAGR of 9% from 2024 to 2034.

 North America led the market and accounted for over 30.50% in 2023 of total sales. Initiatives from the public and commercial sectors, growing pet care costs, and the existence of important players are the main drivers of this expansion. Additionally, the prevalence of zoonotic illnesses is anticipated to increase market growth.

Due to factors like the rising demand for veterinary dermatology drugs and the gradually spreading awareness of these products availability in emerging economies like India and China, the veterinary dermatology drugs market in the Asia Pacific is predicted to experience significant growth over the forecast period. Additionally, the fact that several significant market participants, like Elanco, have production facilities in Asia Pacific helps the region's growth.

Veterinary Dermatology Drugs Market Growth Factors

The primary factors anticipated to propel market expansion include the increased prevalence of skin disorders in animals and significant expenditures made in this area by major industry competitors. The market is predicted to develop as a result of a trend in which pet owners are making more decisions about their pets' care. More than 20% of all animal veterinary consultations are now for dermatological issues. The four most prevalent chronic dermatological illnesses are allergies, otitis externa, seborrheic dermatitis, and surface pyoderma. In order to identify and treat major skin illnesses, the market is being supported by the introduction of cutting-edge medical equipment and technologies as well as an increase in the number of research papers on veterinary dermatology. As a consequence, it is anticipated that throughout the projected period, the rise in veterinary consultation visits would support the expansion of the global market for veterinary dermatology drugs.

Market growth is anticipated to be fueled by the rising prevalence of skin conditions in animals as well as rising industry investment by veterinary pharmaceutical firms. The adoption of new pet treatment options by pet owners is a growing trend in the pet care sector that is expected to fuel market expansion. The rising incidence of skin disorders and significant investments by market participants is the industry's development accelerators. Additionally, pet owners are increasingly making more decisions regarding their pets' care, which is anticipated to drive the market's expansion. Additionally, the global veterinary dermatology medications market is anticipated to see new growth opportunities due to an increase in incidences of dermatological conditions such as allergic dermatitis and flea-and-tick-related disorders. The market is also growing as a result of more clinical studies being conducted with medications for veterinary dermatology.

• The factors anticipated to propel market expansion include the increased prevalence of skin disorders in animals and significant investments made by industry participants in the segment.
• As there are more pet owners, there is a greater demand for improved companion animal treatment alternatives, which raises the cost of pet health care.
• The need for veterinary healthcare products is anticipated to rise as the number of companion animals increases.
• In the near future, it is anticipated that enhanced medical care and quick vaccination delivery would propel the growth rate of the global veterinary dermatology pharmaceuticals market.

Market Scope

Veterinary Dermatology Drugs Market Dynamics

Drivers

Rising prevalence of diseases among animals 

• Comparatively to foot-and-mouth disease, lumpy skin disease can cause permanent weakening in afflicted livestock, making it an economically significant cow illness, according to the Food and Agriculture Organization. Lesions on the skin are the consequence of severe and irreversible damage to hides, and mortality rates of up to 40% or more have been documented. Mouth, throat, and respiratory tract lesions are frequent, leading to rapid decline and, occasionally, severe emaciation that can linger for months. For LSD infection in cattle, there is presently no particular antiviral therapy available. However, two vaccinations for the Neethling and Kenya sheep and goat pox viruses have been successfully marketed worldwide and have been widely utilized in Africa. The aforementioned elements have proven crucial for the growth of the market for veterinary dermatology medications worldwide.

Challenges

Adverse effects of the veterinary dermatology drugs

• Drugs for veterinary dermatology may have negative effects, which limit market expansion. Animals may experience minor to severe difficulties as a result of these negative impacts. Many animal patients are hesitant to use veterinary dermatological medications after seeing such negative consequences. These medications may also cause pets to eat less, which might result in dehydration and other problems.

Imposition of stringent regulations

• To be sold on the market, veterinary dermatology medications need to pass strict requirements. The drug-processing method aids in limiting skin cancer cells' aberrant skin growth. So, in order to be approved, veterinary dermatological medications must first pass a number of tests to demonstrate their safety for the intended purposes.

Opportunities

Development of cutting-edge medical therapies

• Veterinary dermatology medications for dogs have grown in both emerging and developed countries due to the rising prevalence of skin cancer and other chronic disorders. The government and commercial entities are making significant investments in the healthcare sector. For dermatological medications to produce reliable outcomes, further technology development is required. There were certain technological restrictions on earlier treatments and medications. Modern veterinary dermatological medications aid in the successful treatment of cancer cells.

An increase in the cost of veterinary treatment

• The industry is anticipated to experience considerable growth because to rising costs for veterinary health care. The pressure on the pocketbook is caused by an increase in pets, a rise in pet owners taking their animals to the doctor, and a rise in vet costs because of labor costs and more advanced therapies for animals that are adapted from human medicine. The price of new technology and medical supplies, as well as growing drug and medication costs, have all contributed to an increase in the price of veterinary care. In addition to greater expenses, other factors contributing to the increase in spending include an increase in the number of pets and longer pet lifespans, which call for more veterinary care.

Animal Type Insights

The companion animal market segment led and accounted for more than 70.30% 2023 of total revenue. Growing pet ownership is anticipated to accelerate market expansion. Dogs, cats, horses, and other animals are further separated into several segments. Due to the wide availability of products for canine therapy, the dogs category is predicted to have the biggest market share.

In 2023, the livestock animal segment's revenue share was the second-largest. Cattle and other categories are added to it. The increased demand for animal protein and the frequency of parasitic infections in farm animals are anticipated to boost the market for veterinary dermatology medications. Additionally, the category for cattle is anticipated to experience the fastest CAGR of 9.1% throughout the projection period.

Route of Administration Insights

With a market share of 37.40% in 2023, the oral sector led the industry. It is anticipated that the market would rise due to the widespread availability of oral medications in the form of tablets, feed additives, and pills among others. Initiatives taken by market participants in this category are also anticipated to accelerate market expansion. For instance, Bioiberica expanded its offering of dermatological treatments in September 2021 when it introduced the oral and topical dermatology medication line Atopivet.

Since injectable medications allow for simple administration in a substantially lesser number of doses compared to oral medications, the injectable category is anticipated to experience the quickest CAGR of nearly 10.70% throughout the projected period. In contrast to 28 doses of tablets, Convenia from Zoetis cures the animal in just one treatment. Due to its widespread acceptance, the topical category is also anticipated to expand rapidly.

Indication Insights

With a market share of 45.31% in 2023, parasitic infections led the industry. It is anticipated that the market would rise due to the widespread availability of oral medications in the form of tablets, pills, and feed additives, among others. Initiatives taken by market participants in this category are also anticipated to accelerate market expansion. For instance, Bioiberica expanded its offering of dermatological treatments in September 2021 when it introduced the oral and topical dermatology medication line Atopivet.

Since injectable medications allow for simple administration in a substantially lesser number of doses compared to oral medications, the injectable category is anticipated to experience the quickest CAGR of nearly 10.5% throughout the projected period. In contrast to 28 doses of tablets, Convenia from Zoetis cures the animal in just one treatment. Due to its widespread acceptance, the topical category is also anticipated to expand rapidly.

Distribution Channel Insights

Hospital pharmacy led the industry and accounted for 45.50% of all sales in 2023. The expansion of the category is anticipated to be aided by the growing number of hospital pharmacies. Additionally, when it comes to treating their pets or farm animals, animal owners sometimes start by contacting veterinary institutions. As a result, hospital pharmacies are the go-to locations for purchasing prescription pharmaceuticals, accounting for their dominant market position.

During the projection period, the e-commerce segment is anticipated to experience the quickest CAGR of about 10.5%. This rise can be attributed to the increasing use of veterinary telemedicine platforms and e-commerce websites that are specifically dedicated to selling veterinary items. By 2028, the sector's market share is anticipated to surpass that of the retail sector.

Veterinary Dermatology Drugs Market Companies

• Merial, Zoetis, Inc.
• Ceva Sante Animale
• Vetmedica
• IDEXX Laboratories
• Vetoquinol S.A.
• Virbac S.A.
• Bayer Animal Health
• Boehringer Ingelheim
• Elanco
• Novartis Animal Health
• SAVAVET
• Toray Industries
• AB Science 

Recent Developments

• Elanco announced a deal to buy Kindred Biosciences in June 2021 for USD 440 million. With this, Elanco has advanced the market for pet health, particularly in the quickly expanding dermatological sector. By 2025, three brand-new blockbuster dermatological medications from Kindred Biosciences are anticipated to be available.
• Ceva Animal Health introduced Douxo S3 Pyo skincare pads for cats and dogs in January 2021. These pads are expected to improve this range by providing an easy-to-administer antibacterial activity while hydrating and protecting the skin's environment.
• In September 2020, Bioiberica released the two newest products in its dermatological line, Atopivet Mousse and Atopivet oral suspension. The company's goal with this introduction was to treat atopic dermatitis in dogs and cats at all layers of the epidermis and dermis.

Segment Covered in the Report

By Animal Type

• Companion Animal
• Livestock Animal

By Route of Administration

• Oral
• Topical
• Injectable

By Indication

• Parasitic Infections
• Allergic Infections
• Others

By Distribution Channel

• Retail
• E-Commerce
• Hospital Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)